In this supplement to EMJ Oncology, four leading researchers, Frederick Marmé, Christina Fotopoulou, Ursula Matulonis, and David Bowtell, discussed the impact of late diagnosis and delayed treatment on patient outcomes in ovarian cancer, genetic screening, and risk-reduction strategies. The evolving landscape of homologous recombination deficiency (HRD) testing and the importance of HRD testing at diagnosis are also explored.

Professor of Reproductive Health, Robinson Research Institute, Adelaide Gynecologist and REI Subspecialist, Auckland Gynecology Group and Repromed Auckland

Presented by: Chair: Dr. Jonathan Sackier, Speakers: Dr. William Audeh, Dr. Alberto Montero

These supplements to EMJ Dermatology put a spotlight on late-breaking research and ePoster presentations from leading experts that took place at the American Academy of Dermatology (AAD) Virtual Meeting Experience. The ePoster presentations highlighted recent discoveries in innovative trials investigating the comparative efficacies of potential psoriasis treatments.

This episode is on the topic of ovarian cancer. Hear from two experts in the field, Professor Frederik Marmé and Professor Christina Fotopoulou, as they discuss the impact of late diagnosis and delayed treatment on patient outcomes, risk reduction strategies, and HRD testing.

In this podcast, sponsored by Thermo Fisher Scientific, discover the latest in antimicrobial resistance (AMR), specifically the long-term impact of antibiotic overuse in sepsis. Hear from expert, Evangelos Giamarellos-Bourboulis, Professor of Internal Medicine and Director of the Master Programme in Infectious Diseases…

Massimiliano Siciliano, Digital Solution Director Europe, Novartis, talks about the potential of digital solutions for pharma stakeholders.